

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A hybrid antigen comprising at least one antigenic domain of an infectious agent or tumor antigen and a binding domain that non-covalently binds to a heat shock protein, wherein the binding domain comprises Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:417), Phe Tyr Gln Leu Ala Leu Thr Trp (SEQ ID NO:186), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:419).
2. (previously presented) The hybrid antigen of Claim 1 wherein a peptide linker separates the antigenic domain and the binding domain.
3. (canceled)
4. (previously presented) A composition comprising at least one hybrid antigen of Claim 1 and a pharmaceutically acceptable carrier.
5. (previously presented) A method for inducing an immune response in a subject to an infectious agent comprising administering to the subject at least one hybrid antigen of Claim 1, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent.
6. (currently amended) A method for inducing an immune response in a subject to an infectious agent comprising administering to the subject a complex of:
  - (a) at least one hybrid antigen of Claim 1, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent; and
  - (b) at least one said heat shock protein;wherein the hybrid antigen and the at least one said heat shock protein are non-covalently bound.
7. (currently amended) The method of claim 6 wherein the at least one said heat shock protein is a hsp70 family member.

8. (currently amended) A method for treating an infectious disease comprising administering to a subject having an infectious disease at least one hybrid antigen of Claim 1, which said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent ~~is associated with~~ causes said infectious disease.
9. (currently amended) A method for treating an infectious disease comprising administering to a subject having an infectious disease a complex of:
- (a) at least one hybrid antigen of Claim 1, wherein said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent ~~is associated with~~ causes said infectious disease; and
  - (b) at least one said heat shock protein;
- wherein the hybrid antigen and the at least one said heat shock protein are non-covalently bound.
10. (currently amended) The method of claim 9 wherein the at least one said heat shock protein is a hsp70 family member.
11. (previously presented) A hybrid antigen consisting essentially of at least one antigenic domain of an infectious agent or tumor antigen, a binding domain that non-covalently binds to a heat shock protein, and a peptide linker separating the antigenic domain and the binding domain, and wherein the binding domain comprises Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:417), Phe Tyr Gln Leu Ala Leu Thr Trp (SEQ ID NO:186), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:419).
12. (canceled)
13. (previously presented) A composition comprising at least one hybrid antigen of Claim 11 and a pharmaceutically acceptable carrier.
14. (previously presented) A method for inducing an immune response in a subject to an infectious agent comprising administering to the subject at least one hybrid antigen of

Claim 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent.

15. (currently amended) A method for inducing an immune response in a subject to an infectious agent comprising administering to the subject a complex of:

- (a) at least one hybrid antigen of Claim 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent; and
- (b) at least one said heat shock protein;

wherein the hybrid antigen and the at least one said heat shock protein are non-covalently bound.

16. (currently amended) The method of claim 15 wherein the at least one said heat shock protein is a hsp70 family member.

17. (currently amended) A method for treating an infectious disease comprising administering to a subject having an infectious disease at least one hybrid antigen of Claim 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent ~~is associated with~~ causes said infectious disease.

18. (currently amended) A method for treating an infectious disease comprising administering to a subject having an infectious disease a complex of:

- (a) at least one hybrid antigen of Claim 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent ~~is associated with~~ causes said infectious disease; and
- (b) at least one said heat shock protein;

wherein the hybrid antigen and the at least one said heat shock protein are non-covalently bound.

19. (currently amended) The method of claim 18 wherein the at least one said heat shock protein is a hsp70 family member.

20. (previously presented) A peptide that is Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:417), Phe Tyr Gln Leu Ala Leu Thr Trp (SEQ ID NO:186), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:419).
21. (previously presented) A method for inducing an immune response in a subject to a tumor antigen comprising administering to the subject at least one hybrid antigen of Claim 1 or 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said tumor antigen.
22. (currently amended) A method for inducing an immune response in a subject to a tumor antigen comprising administering to a subject a complex of:
- (a) at least one hybrid antigen of Claim 1 or 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said tumor antigen; and
  - (b) at least one said heat shock protein;
- wherein the hybrid antigen and the at least one said heat shock protein are non-covalently bound.
23. (currently amended) The method of claim 22 wherein the at least one said heat shock protein is a hsp70 family member.
24. (previously presented) A method for treating cancer comprising administering to a subject having a cancer at least one hybrid antigen of Claim 1 or 11, which said at least one hybrid antigen comprises at least one antigenic domain of a tumor antigen, and wherein said tumor antigen is associated with said cancer.
25. (currently amended) A method for treating cancer comprising administering to a subject having a cancer a complex of:
- (a) at least one hybrid antigen of Claim 1 or 11, which said at least one hybrid antigen comprises at least one antigenic domain of a tumor antigen, and wherein said tumor antigen is associated with said cancer; and
  - (b) at least one said heat shock protein;
- wherein the hybrid antigen and the at least one said heat shock protein are non-covalently bound.

26. (currently amended) The method of claim 25 wherein the at least one said heat shock protein is a hsp70 family member.
27. (previously presented) The hybrid antigen of claim 1 or 11, wherein said hybrid antigen is in the range of 10-500 amino acids.
28. (previously presented) The hybrid antigen of claim 1 or 11, wherein said antigenic domain is of an infectious agent.
29. (previously presented) The hybrid antigen of claim 1 or 11, wherein said antigenic domain is of a tumor antigen associated with a ~~neoplastic-disease~~ cancer.
30. (previously presented) The hybrid antigen of claim 29, wherein the ~~neoplastic-disease~~ cancer is selected from the group consisting of sarcoma, lymphoma, leukemia, melanoma, carcinoma of the breast, carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix, uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma, and astrocytoma.
31. (previously presented) The hybrid antigen of claim 28, wherein the infectious agent is selected from the group consisting of a bacterium, a virus, a protozoan, a mycoplasma, a fungus, a yeast, a parasite, and a prion.
32. (previously presented) The hybrid antigen of claim 31, wherein the infectious agent is a bacterium.
33. (previously presented) The hybrid antigen of claim 32, wherein the bacterium is selected from the group consisting of *Salmonella*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Escherichia*, *Klebsiella*, *Vibrio*, *Mycobacterium*, and *Mycoplasma pneumoniae*.
34. (previously presented) The hybrid antigen of claim 31, wherein the infectious agent is a virus.
35. (previously presented) The hybrid antigen of claim 34, wherein the virus is selected from the group consisting of a human papilloma virus, herpes virus, retrovirus, hepatitis virus, influenza virus, rhinovirus, respiratory syncytial virus,

cytomegalovirus, adenovirus, herpes simplex virus, herpes zoster virus, human immunodeficiency virus 1, and human immunodeficiency virus 2.

36. (previously presented) The hybrid antigen of claim 31, wherein the infectious agent is a protozoan.
37. (previously presented) The hybrid antigen of claim 36, wherein the protozoan is selected from the group consisting of an amoeba, a malarial parasite, or *Trypanosoma cruzi*.
38. (currently amended) A composition comprising a non-covalent complex of at least one hybrid antigen of claim 1 or 11 and at least one said heat shock protein; and a pharmaceutically acceptable carrier.
39. (currently amended) The composition of claim 38, wherein the at least one said heat shock protein is a hsp70 family member.
40. (previously presented) The composition of claim 39, wherein the hsp70 family member is BiP, hsp70 or hsc70.
41. (previously presented) The composition of claim 4 or 13 further comprising one or more adjuvants.
42. (previously presented) The composition of claim 38 further comprising one or more adjuvants.
43. (previously presented) A composition comprising a plurality of the hybrid antigens of claim 1 or 11.
44. (currently amended) A composition of claim 43 further comprising a plurality of heat shock proteins non-covalently complexed to the hybrid antigens.
45. (previously presented) The method of claim 5, 6, 14 or 15 wherein the subject is a human.
46. (previously presented) The method of claim 21 wherein the subject is a human.

47. (previously presented) The method of claim 22 wherein the subject is a human.